Switching to bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced (TE) people with HIV (PWH) with baseline symptoms of depression, anxiety or insomnia (DAI) in the observational BICSTaR study

被引：0
|
作者：
Cano-Smith, J. [1 ]
Delgado-Hierro, A. [1 ]
Valencia, E. [1 ]
Ramos, L. [1 ]
Busca, C. [1 ]
Mican, R. [1 ]
Martin-Carbonero, L. [1 ,2 ]
Montes, M. L. [1 ,2 ]
De Miguel, R. [1 ,2 ]
Montejano, R. [1 ]
Moreno, V. [1 ]
Perez-Sadaba, F. [3 ]
Perez-Rambla, C. [3 ]
Molina, R. [4 ]
Gonzalez-Garcia, J. [1 ]
Bernardino, J. I. [1 ]
机构：
[1] Hosp La Paz Carlos III, HIV Unit, IdiPaz, Dept Internal Med, Madrid, Spain
[2] Ctr Invest Biomed Red Enfermedades Infecciosas CI, Madrid, Spain
[3] Outcomes 10 SLU, Castellon De La Plana, Spain
[4] Fdn SEIMC GESIDA, Madrid, Spain
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
EACS2023:
引用
收藏
页码：411 / 412
页数：2
相关论文
共 50 条
  • [21] Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adult patients living with HIV-1 in routine clinical practice: 6-month results of the BICSTaR cohort
    Esser, S.
    Jessen, H.
    Schneider, J.
    Schellberg, S.
    Stellbrink, H. J.
    Waizmann, M.
    Hillenbrand, H.
    Bilbao, P.
    Schreiber, S.
    Thorpe, D.
    Ramroth, H.
    Haubrich, R.
    Robinson, C.
    Heinzkill, M.
    HIV MEDICINE, 2020, 21 : 17 - 17
  • [22] Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice-6 months results of the BICSTaR cohort
    Esser, S.
    Jessen, H.
    Schneider, J.
    Schellberg, S.
    Stellbrink, H-J
    Waizmann, M.
    Hillenbrand, H.
    Bilbao, P.
    Schreiber, S.
    Thorpe, D.
    Ramroth, H.
    Haubrich, R.
    Heinzkill, M.
    HIV MEDICINE, 2019, 20 : 61 - 61
  • [23] Week 48 outcomes from the BRAAVE 2020 study: a randomised switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in African American adults with HIV
    Hagins, D.
    Kumar, P.
    Wurapa, A.
    Brar, I.
    Berger, D.
    Osiyemi, O.
    Hileman, C.
    Ramgopal, M.
    McDonald, C.
    Blair, C.
    Andreatta, K.
    Collins, S. E.
    Brainard, D.
    Gohlar, G.
    Martin, H.
    HIV MEDICINE, 2021, 22 : 33 - 34
  • [24] Switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV aged 65 years or older: W24 results of the BICOLDER study - IMEA 057
    Allavena, C.
    Joly, V.
    Assoumou, L.
    Isernia, V.
    Ajana, F.
    Neau, D.
    Descamps, D.
    Charpentier, C.
    Benalycherif, A.
    Metivier, E.
    Peytavin, G.
    Phung, B.
    Landman, R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 47 - 47
  • [25] Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study
    De Castro, Nathalie
    Brun, Alexandre
    Sellier, Pierre
    Hamet, Gwenn
    Mechai, Frederic
    Garrait, Valerie
    Chabrol, Amelie
    Bouldouyre, Marie-Anne
    Froguel, Eric
    Troisvallets, Didier
    Caraux-Paz, Pauline
    Delaugerre, Constance
    Rozenbaum, Willy
    Molina, Jean-Michel
    AIDS RESEARCH AND THERAPY, 2023, 20 (01)
  • [26] Three-year B/F/TAF use in treatmentnaive (TN) and treatment-experienced (TE) PLWH in the BICSTaR study in Canada, France and Germany
    Schellberg, S.
    Khaykin, P.
    Wyen, C.
    De Wet, J.
    Wong, A.
    Duvivier, C.
    Robineau, O.
    Albuquerque, B.
    Schreiber, S.
    Thorpe, D.
    Heinzkill, M.
    Sahali, S.
    Saifi, T.
    Cassidy, T.
    Spinner, C. D.
    HIV MEDICINE, 2023, 24 : 9 - 10
  • [27] Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study
    Nathalie De Castro
    Alexandre Brun
    Pierre Sellier
    Gwenn Hamet
    Frédéric Mechaï
    Valérie Garrait
    Amélie Chabrol
    Marie-Anne Bouldouyre
    Eric Froguel
    Didier Troisvallets
    Pauline Caraux-Paz
    Constance Delaugerre
    Willy Rozenbaum
    Jean-Michel Molina
    AIDS Research and Therapy, 20
  • [28] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV (PLWH): 12-month (12M) effectiveness, persistence and safety in a multi-country cohort study
    Mallolas, Josep
    Esposito, Vincenzo
    Hocqueloux, Laurent
    Lambert, John S.
    Levy, Itzchak
    Wyen, Christoph
    van Welzen, Berend
    Ustianowski, Andrew
    Schreiber, Sandra
    Thorpe, David
    Heinzkill, Marion
    Marongiu, Andrea
    Haubrich, Richard
    Loemba, Hugues
    HIV MEDICINE, 2022, 23 : 29 - 29
  • [29] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV (PLWH): 12-month (12M) effectiveness, persistence, and safety in a multi-country cohort study
    Mallolas, J.
    Esposito, V.
    Hocqueloux, L.
    Lambert, J. S.
    Levy, I.
    Wyen, C.
    van Welzen, B.
    Ustianowski, A.
    Schreiber, S.
    Thorpe, D.
    Heinzkill, M.
    Marongiu, A.
    Haubrich, R.
    Loemba, H.
    HIV MEDICINE, 2021, 22 : 115 - 116
  • [30] Use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in kidney transplant recipients living with HIV-1 receiving calcineurin and mTOR inhibitors: a pilot switch study
    Gallien, Sebastien
    Assoumou, Lambert
    Dantal, Jacques
    Hulin, Anne
    Benalycherif, Aida
    Ben Rayana, Raida
    Tobbal, Yasmine
    Matignon, Marie
    Melica, Giovanna
    Allavena, Clotilde
    Stehle, Thomas
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 286 - 287
12345